ABSTRACT Background Patients with head and neck cancer (HNC) receiving curative‐intent radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) experience high symptom burden and acute treatment‐related toxicities. Supportive Care (SC) can mitigate these effects; however, the timing and documented triggers for referral are insufficiently characterized in routine practice. Methods We conducted a prospective, observational longitudinal cohort study (April 2023–March 2024) at a tertiary cancer center in India. Consecutive eligible adults with HNC receiving curative‐intent RT/CCRT were enrolled ( n = 96). Referral timing (days from RT initiation) and documented reasons were extracted from the electronic medical record (EMR). Symptom burden (ESAS‐r Edmonton Symptom Assessment Scale‐Revised), quality of life (FACT‐HN), and toxicities (NCI CTCAE v5 National Cancer Institute Common Terminology Criteria for Adverse Events Version 5) were assessed at the first SC visit and at five follow‐up visits over 8 weeks. Missing follow‐up outcomes were imputed using the last observation carried forward (LOCF) method. Changes across visits were assessed using the Friedman test, with Kendall's W reported as an effect size. Results The mean age was 56.35 years (SD 12.83); 70 (72.9%) were men. Half of the cohort lacked a documented referral reason in the EMR. Referrals occurred predominantly during the second and third treatment weeks (mean 19.2 days from RT initiation; SD 12.66; range 0–71 days). The timing of referral correlated strongly with the RT fractions received (Spearman's ρ = 0.942, p < 0.001). Pain improved from a median of 5 to 2 (χ 2 = 141.68, p < 0.001; W = 0.30). Anxiety improved from a median of 3 to 2 (χ 2 = 54.51, p < 0.001; W = 0.11). Total FACT‐HN improved from a median of 83.7 to 96.7 (χ 2 = 79.88, p < 0.001; W = 0.17). Conclusions SC referrals for HNC patients are commonly reactive during peak acute toxicity periods rather than proactive. Structured referral triggers and improved EMR documentation may enhance timely symptom control and quality of life during curative treatment.
Gayatri et al. (Wed,) studied this question.